Adoptive cell transfer: a clinical path to effective cancer immunotherapy
By S. Rosenberg, N. Restifo, Jie Yang, R. Morgan, M. Dudley. Nature Reviews. Cancer, 2008
1,698 citations recorded by the source corpus.
Subfields: Genetics, Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/13820e67b7314a8e9e62008e5184c1e8332a93d2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Immunology
In Oncology
Citations in the corpus
- Regulation of PD-L1: a novel role of pro-survival signalling in cancer. (2016, background): “These include administration of immune-stimulating cytokines such as interferon (IFN) and interleukin-2, active immunization to enhance endogenous immune responses such as dendritic cell (DC)-based vaccination, adoptive cell-transfer therapy using autologous cancer-specific cytotoxic T-cells (CTLs) ”
- CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. (2011, background): “Introduction As T cell immunotherapy extends into clinical application (1, 2), its benefits are being expanded by engineering T lymphocytes to express chimeric antigen receptors (CARs) that recognize specific antigens expressed on the cell surface of different types of tumor cells (3–8).”
- Interleukin 12: still a promising candidate for tumor immunotherapy? (2014, background): “The major limitation was a short half-time of circulation of the infused cells and their poor homing to the tumor (for review, see [166]).”
- Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. (2010, background): “one of the most successful forms of immunotherapy incorporates adoptive transfer of autologous T lymphocytes after a lymphodepleting preconditioning regimen (10).”
- Innovative approaches for cancer treatment: current perspectives and new challenges (2019, background): “Immunotherapy can be achieved by another strategy called adoptive cell transfer (ACT) and it consists of isolating T-lymphocytes (T-cells) with the highest activity against cancer directly from the patient’s blood, expanding them ex vivo, and reinfusing them again into the patient [154].”
- The therapeutic promise of the cancer stem cell concept. (2010, background): “Moreover, these results indicate that CSC interactions with host immunity might contribute to the variability of experimentally determined CSC frequencies in human to mouse xenotransplantation models with varying degrees of host immunocompetence (13–15, 17, 18), and that CSC immunomodulatory functio”
- Nanoparticles for Cancer Therapy: Current Progress and Challenges (2021, background): “These cancers create an unusual extracellular matrix (ECM) which is quite challenging for immune cells to infiltrate [12].”
- Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells (2011, background): “, 2010), unless a high number of CTLs are administered, as required by many clinical ACT protocols (Rosenberg et al., 2008).”